首页> 美国卫生研究院文献>Oncology Reports >New molecular staging with G-factors (VEGF-C and Reg IV) by supplementing TNM classification in colorectal cancers
【2h】

New molecular staging with G-factors (VEGF-C and Reg IV) by supplementing TNM classification in colorectal cancers

机译:通过补充TNM分类在大肠癌中使用G因子(VEGF-C和Reg IV)进行新的分子分期

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Staging classification of colorectal cancers is performed by the UICC/TNM classification system, which is the global gold standard. However, we often experience in clinical practice that there are considerable differences in prognoses between patients who have the same classification particularly in stage II and III cancers. The aim of this study was to propose a new TNM-G classification to predict prognosis and recurrence by supplementing the conventional TNM classification. A total of 220 cases of colorectal cancer, including 77 at stage II and 143 at stage III, were registered from four independent facilities. Immunohistochemical staining for 7 molecules, such as p53, vascular endothelial growth factor (VEGF)-A, VEGF-C, regenerating islet-derived family, member 4 (Reg IV), olfactomedin 4, Claudin-18 and matrix metalloproteinase-7 (MMP-7), was performed to investigate the correlation between clinicopathological factors and expression of each molecule. Based on the results, no significant correlation was observed between the immunostaining expression of these 7 factors and recurrence in total colorectal cancer. Recurrence in stage II (77 cases) was significantly higher in cases positive for Reg IV expression (P=0.042). On analysis of overall survival (OS) and disease-free survival (DFS), VEGF-C and Reg IV expression had a correlation with poor prognosis, therefore, these factors were selected and applied to G-factor classifications so that cases negative for both could be classified as G0, cases positive for either of the factors could be classified as G1, and cases positive for both factors could be classified as G2. While no significant correlation was observed in the recurrence rates between G0 and G2, OS and DFS in stage II cases were significantly poorer for G2 cases in comparison with G0 or G1 cases. The survival curves of OS and DFS in stage II G2 were similar to that of stage III cases. According to these results, prognosis of VEGF-C/Reg IV both positive G2 cases in stage II colorectal cancer was found to be almost equal to the poor survival in stage III cases, and the advancement of one stage up migration based on G-factors may be supposed to be highly feasible for clinical application. In conclusion, the combination of VEGF-C and Reg IV may be a promising factor for clinical staging to supplement the classical TNM classification system, and it may suggest a good indication of adjuvant chemotherapy for G2 cases in stage II colorectal cancers.
机译:大肠癌的分期分类由UICC / TNM分类系统执行,这是全球金标准。但是,我们在临床实践中经常会发现,具有相同分类的患者之间的预后存在很大差异,尤其是在II期和III期癌症中。这项研究的目的是提出一种新的TNM-G分类法,通过补充常规TNM分类法来预测预后和复发。从四个独立机构共登记了220例结直肠癌病例,包括II期77例和III期143例。免疫组织化学染色的7个分子,例如p53,血管内皮生长因子(VEGF)-A,VEGF-C,再生胰岛来源的家族,成员4(Reg IV),嗅觉素4,克劳丁18和基质金属蛋白酶7(MMP) -7),以研究临床病理因素与每个分子表达之间的相关性。根据结果​​,这7种因子的免疫染色表达与总结直肠癌的复发之间未发现显着相关性。 Reg IV表达阳性的病例II期的复发(77例)明显更高(P = 0.042)。通过对总生存期(OS)和无病生存期(DFS)的分析,VEGF-C和Reg IV表达与不良预后相关,因此,选择了这些因素并将其应用于G因子分类,因此这两种情况均为阴性可以将其归类为G0,将这两个因素中的任何一个都为正的情况归为G1,将两个因素都为正的情况都归为G2。虽然在G0和G2之间的复发率上没有观察到显着相关性,但是与G0或G1病例相比,II期病例的OS和DFS明显低于G2病例。 II期G2期OS和DFS的生存曲线与III期病例相似。根据这些结果,发现VEGF-C / Reg IV均在II期大肠癌中阳性的G2病例的预后几乎与III期患者的不良存活率相等,并且基于G因子向上一级迁移的进展可能被认为对于临床应用是高度可行的。总之,VEGF-C和Reg IV的组合可能是临床分期以补充经典TNM分类系统的有希望的因素,并且可能为II期大肠癌的G2病例建议辅助化疗的良好指征。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号